Efficacy and Safety of the Traditional Chinese Medicine Yunnan Baiyao in the Treatment of Diabetic Foot Ulcers: a Multicentre, Randomised Clinical Trial
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70253 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Ying Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetic Foot, Drugs, Chinese Herbal, Wound Healing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Peking University-Yunnan Baiyao joint research fund.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Diabetic foot ulcers (DFUs) constitute an increasing clinical challenge, driven by the escalating prevalence of diabetes and the paucity of effective therapies. This multicentre, randomised, open‐label, blinded‐endpoint trial investigated the efficacy and safety of Yunnan Baiyao (YNBY), a traditional Chinese medicine, as an adjunctive therapy for DFUs. Patients with DFUs (Wagner Grade 3 or 4) from three hospitals were randomised 2:2:1 to YNBY powder, YNBY ointment and control groups, all receiving standard of care. A total of 117 patients completed the trial. The 2‐week percentage of wound area reduction (PWAR) was significantly higher in YNBY powder (61.5%) and YNBY ointment (70.0%) groups than that in the control group (46.4%, p < 0.01). The 1‐week PWAR was almost doubled in the YNBY powder group (36.1%) and the YNBY ointment group (42.9%) relative to the control group (19.5%, p < 0.05). The percentage of complete healing within 8 weeks (control group, 25.0%; powder group, 54.2%; ointment group, 61.9%) did not reach statistical significance. No significant differences were observed between the YNBY powder and ointment groups. The adjunctive use of YNBY powder or ointment with standard therapy significantly accelerates wound closure. This effective, inexpensive, easy‐to‐apply traditional medicine can serve as an effective adjunct to standard DFUs care. Trial registration: https://clinicaltrials.gov/ , NCT06197412 (Registration Date: 12/17/2023)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking University Third Hospital, Beijing, China.
- Department of Wound Healing Center, Peking University Third Hospital, Beijing, China.
- Department of Wound Healing Center, Beijing Haidian Hospital, Beijing, China.
- Department of General Surgery, Beijing Zhongguancun Hospital, Beijing, China.
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
- Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
ORCID-Profile: Ying Zhang, Yunfeng Li, Hua Zhang, Lu Tie
Förderung
- Peking University-Yunnan Baiyao joint research fund
Zitieren
APA
Zhang, Y., Zhao, J., Huang, E., Li, Y., Yin, X., Zhang, J., Lin, Y., Zhang, H., Zhang, C., Tie, L., Wang, W., & Zhang, L. (2026). Efficacy and Safety of the Traditional Chinese Medicine Yunnan Baiyao in the Treatment of Diabetic Foot Ulcers: a Multicentre, Randomised Clinical Trial. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70253
Vancouver
Zhang Y, Zhao J, Huang E, Li Y, Yin X, Zhang J, et al. Efficacy and Safety of the Traditional Chinese Medicine Yunnan Baiyao in the Treatment of Diabetic Foot Ulcers: a Multicentre, Randomised Clinical Trial. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70253
BibTeX
@article{Zhang2026,
author = {Zhang, Ying and Zhao, Jinghui and Huang, Ershun and Li, Yunfeng and Yin, Xiankun and Zhang, Jun and Lin, Yanming and Zhang, Hua and Zhang, Chunlei and Tie, Lu and Wang, Wenhui and Zhang, Long},
title = {Efficacy and Safety of the Traditional Chinese Medicine Yunnan Baiyao in the Treatment of Diabetic Foot Ulcers: a Multicentre, Randomised Clinical Trial},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70253}
}
EUVIMED